PharmaCyte Biotech Raises Additional $1 Million for Pancreatic Cancer Clinical Trial

SILVER SPRING, Md., Jan. 14, 2016, PMCB, (GLOBE NEWSWIRE) PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the Company raised an additional $1 million. A Form 8-K was filed yesterday with the SEC providing the details of the capital raise. PharmaCyte has shown repeatedly the ability to raise the funds necessary to get into a pancreatic cancer clinical trial and to continue its work in both pancreatic cancer and diabetes. PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We have a lot of work ahead of us this year at PharmaCyte. With the recently announced private placement of just over $1 million, we have not only increased our cash on hand to over $3.0 million but have increased our leverage in the capital markets. What is mission critical for PharmaCyte is getting into a panc


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: